{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Invivyd, Inc.
Is Invivyd, Inc. overvalued or undervalued?
As of August 14, 2024, Invivyd, Inc. is rated as risky due to its negative P/E ratio and poor returns on capital and equity, indicating it may be overvalued compared to peers, despite recent short-term gains.
Is Invivyd, Inc. technically bullish or bearish?
As of May 1, 2024, Invivyd, Inc. shows a mildly bullish trend supported by weekly and monthly MACD readings, despite short-term bearish signals from daily moving averages and mixed indicators overall.
What does Invivyd, Inc. do?
Invivyd, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $11 million and a net loss of $16 million as of March 2025, with a market cap of $87.19 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -263.57%.
How big is Invivyd, Inc.?
As of Jun 18, Invivyd, Inc. has a market capitalization of 87.19 million, with net sales of 36.68 million and a net profit of -142.72 million over the last four quarters. Shareholder's funds are 67.54 million, and total assets amount to 129.51 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
